Nexalin Technology (NXL) Registration filing summary

Company overview and business model

• Designs and develops non-invasive neurostimulation devices for mental health conditions, focusing on anxiety, insomnia, depression, and other neurological disorders.

• Devices use proprietary waveform technology, with Gen-2 and Gen-3 models emitting a 15 milliamp current for deeper brain stimulation.

• Revenue streams include device sales, monthly licensing, and recurring sales of proprietary single-use electrodes.

• Joint venture in Hong Kong with Wider Come Limited enables clinical development and commercialization in China and the region.

• Plans to launch a virtual clinic model for home-based treatment, integrating telehealth and digital management platforms.

Financial performance and metrics

• Incurred comprehensive losses of $4.7 million in 2023 and $1.0 million in Q1 2024; accumulated deficit of $78.1 million as of March 31, 2024.

• Limited sales to date, with revenue primarily from legacy device servicing and consumables.

• Ongoing need for additional funding to support operations, R&D, and commercialization efforts.

Use of proceeds and capital allocation

• Net proceeds from the offering will be used for general corporate purposes, including working capital, operating expenses, and capital expenditures.

• Proceeds may also be allocated to strategic opportunities such as acquisitions, joint ventures, or licensing.